Literature DB >> 29679911

The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children.

Nafiye Polat Çiçek1, Tülay Kamaşak2, Mine Serin3, Aysenur Okten4, Ahmet Alver5, Ali Cansu6.   

Abstract

PURPOSE: Although some drugs used in the treatment of epilepsy are known to affect body weight, the hormonal factors responsible have not been sufficiently described. The purpose of this study was to compare insulin, leptin, neuropeptide Y and ghrelin levels in children with epilepsy receiving monotherapy with topiramate (TPM) and valproic acid (VPA), the drugs whose effects on body weight have been most discussed, with those of a control group.
METHOD: 48 patients (25 VPA, 23 TPM) aged between 6 and 15.5 years, presenting to the Karadeniz Technical University Medical Faculty Pediatric Neurology Clinic, diagnosed with idiopathic epilepsy or location-related idiopathic epilepsy, and receiving VPA or TPM monotherapy for at least 6 months were included in the study. Twenty-five healthy subjects with similar demographic characteristics were enrolled as the control group. Blood samples were collected from the patient and control groups after fasting for at least 10-12 h and again 1 and 2 h postprandially. Body mass index (BMI) values were calculated for all cases. VPA levels, glucose, insulin, leptin, neuropeptide Y and ghrelin were investigated in all three separate blood samples.
RESULTS: Age, height, weight and BMI were similar between the patient and control groups. Significant weight gain was observed throughout treatment in the VPA group compared to the TPM group. High fasting and postprandial insulin levels were observed in the VPA group. VPA group leptin and neuropeptide Y (NPY) levels were also higher than in the TPM and control groups. No significant difference was determined in ghrelin levels in the patient groups compared to the controls.
CONCLUSION: Low blood sugar not being observed, even though insulin levels are high, after fasting and in the postprandial period in epileptic children receiving VPA is indicative of insulin resistance. The elevation in leptin and neuropeptide Y levels observed in the VPA group also suggest this.
Copyright © 2018 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiepileptic drugs; Endocrine side-effect; Ghrelin; Glucose; Insulin; Leptin; NPY; Topiramate; Valproic acid

Mesh:

Substances:

Year:  2018        PMID: 29679911     DOI: 10.1016/j.seizure.2018.03.013

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  6 in total

1.  Valproate-Induced Epigenetic Upregulation of Hypothalamic Fto Expression Potentially Linked with Weight Gain.

Authors:  Huan Zhang; Ping Lu; Hui-Ling Tang; Hua-Juan Yan; Wei Jiang; Hang Shi; Si-Yu Chen; Mei-Mei Gao; Xiang-Da Zeng; Yue-Sheng Long
Journal:  Cell Mol Neurobiol       Date:  2020-06-04       Impact factor: 5.046

2.  Lipidomic characteristics and clinical findings of epileptic patients treated with valproic acid.

Authors:  Rong Li; Xingyue Qin; Xiaoliu Liang; Meizhen Liu; Xiaoxi Zhang
Journal:  J Cell Mol Med       Date:  2019-06-04       Impact factor: 5.310

3.  Reduction of Mitophagy-Related Oxidative Stress and Preservation of Mitochondria Function Using Melatonin Therapy in an HT22 Hippocampal Neuronal Cell Model of Glutamate-Induced Excitotoxicity.

Authors:  Dan-Dan Wang; Mei-Fang Jin; Dong-Jing Zhao; Hong Ni
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-08       Impact factor: 5.555

Review 4.  Research Progress on the Effect of Epilepsy and Antiseizure Medications on PCOS Through HPO Axis.

Authors:  Shuang Li; Linhai Zhang; Nian Wei; Zhenzhen Tai; Changyin Yu; Zucai Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-21       Impact factor: 5.555

5.  What Is the Effect of Topiramate Use on Growth in Children With Epilepsy?

Authors:  Muhammad T Alrifai; Noura A Alsubaie; Albatool M Abodarahem; Shadan B Alomran; Maryam N Alboqami; Raghad T Alsadun; Yusra Sajid Chachar; Mohammed A Alqassim; Mohamed K Abdelkabir
Journal:  Cureus       Date:  2022-08-28

Review 6.  Targeting the Ghrelin Receptor as a Novel Therapeutic Option for Epilepsy.

Authors:  An Buckinx; Dimitri De Bundel; Ron Kooijman; Ilse Smolders
Journal:  Biomedicines       Date:  2021-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.